Pancreatic cancer (PC) is the seventh and third leading cause of cancer deaths in Taiwan and the U.S., respectively. Patient survival dramatically shortens once the PC grows beyond 2 cm. Computed tomography (CT) is the major detection modality for PCs. However, approximately 40% of PCs less than 2 cm are missed on CT, and the accuracy of CT image interpretation is influenced by radiologist experience and workload. To fulfill this unmet clinical need, we developed PANCREASaver, the first AI-based computer-aided detection tool for PC which can determine whether CT images harbor PC and indicate the tumor's location.
PANCREASaver, an AI-based detection tool, can differentiate pancreatic cancer from normal pancreas on CT images with an accuracy exceeding 90% and facilitates the detection of PCs.
PANCREASaver has been featured in top international journals such as 'The Lancet Digital Health' and 'Radiology,' and has received recognitions, including the 'National Innovation Award,' 'National Innovation Advancement Award,' 'Symbol of National Quality (SNQ),' and 'Taipei Biotech Award.' The product holds four Taiwan invention patents and four U.S. invention patents. In July 2023, it received medical device approval from the Taiwan Ministry of Health and Welfare and was recognized by the U.S. FDA as a breakthrough medical device.
